CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

SARS-CoV-2 research in nasopharyngeal swab, sperm and serologicsWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug738 Continuous Positive Airway Pressure Wiki 1.00

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Presence of SARS-CoV-2 in Semen: Impact on Fertility Preservation in Male Oncological Patients During the COVID-19 Pandemic ?

During the COVID-19 pandemic, the French Agency of Biomedicine has recommended maintaining fertility preservation for patients requiring immediate oncological treatments exhibiting gonadotoxic effects. However, no study has examined the presence of SARS-CoV-2 in sperm from cancer patients. This study aims therefore to detect the presence of SARS-CoV-2, specifically in the seminal fluid and the spermatozoa fractions of cancer patient semen. The investigators will determine if the virus presence in sperm is associated with its presence in the nasal swabs, COVID symptoms, specific serological profiles and particular oncological pathologies/treatments.

NCT04487639 Sperm Preservation in Oncological Patients Fertility Cryopreservation Diagnostic Test: SARS-CoV-2 research in nasopharyngeal swab, sperm and serologics

Primary Outcomes

Description: Seminal fluid and spermatozoa will be separated by density gradient centrifugation, and SARS-CoV-2 will be detected by RT-qPCR in the both fractions.

Measure: Detection of SARS-CoV-2 in sperm during fertility preservation procedures by RT-qPCR

Time: Semen collection day (Day0)

Secondary Outcomes

Description: We will compare SARS-CoV-2 RT-PCR results of seminal fluid and the spermatozoa fractions of the same ejaculate

Measure: To correlate the presence of SARS-CoV-2 in the seminal fluid and the spermatozoa fractions of the same ejaculate

Time: Semen collection day (Day0)

Description: we will correlate the SARS-CoV-2 detection (using RT- qPCR) in nasopharyngeal swab, seminal fluid and spermatozoa fractions

Measure: To determine if the presence of this virus in sperm is associated with its presence in nasal swabs

Time: Semen collection day (Day0)

Description: Any patient undergoing oncological fertility preservation will be evaluated for COVID-19 symptomatology (fever, cough, headache, myalgia, diarrhea, anosmia, pharyngodynia). We will correlate the SARS-CoV-2 detection in seminal fluid and spermatozoa fractions with COVID symptoms

Measure: To determine if the presence of this virus in sperm is associated with COVID symptoms

Time: Semen collection day (Day0)

Description: Serological tests (Sars-CoV2) will be carried out. We will correlate the SARS-CoV-2 detection in seminal fluid and spermatozoa fractions with specific COVID serological profiles

Measure: To determine if the presence of this virus in sperm is associated with specific serological profiles

Time: Semen collection day (Day0) and 30 to 50 days after (Day 30 to 50)

Description: We will correlate the SARS-CoV-2 detection in seminal fluid and spermatozoa fractions with patient's oncological pathologies and treatments

Measure: To determine if the presence of this virus in sperm is associated with particular oncological pathologies/treatments

Time: Semen collection day (Day0)

Description: Before semen density gradient centrifugation and cryopreservation, standards sperm analysis will be performed according to the WHO guideline (2020). We will correlate the SARS-CoV-2 detection in seminal fluid and spermatozoa fractions with standards sperm parameters

Measure: To determine if the presence of this virus in sperm could impair its quality

Time: Semen collection day (Day0)

No related HPO nodes (Using clinical trials)